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Summary
Substantial evidence indicates a close relationship between eosinophils and basophils. We examined
whether interleukin 5 (IL5), known to be eosinophilopoietic and capable ofselectively regulating
eosinophil functions, has an affect on basophil functions. IL5 enhanced basophil histamine release
evoked by anti-IgE, formyl-methionyl-leucyl-phenylalanine, or ionophore A23187 at picomolar
concentrations. Direct action of IL5 on human basophils was confirmed using highly purified
basophil populations. These observations reveal the novel fact that IL5 is able to modulate basophil
functions as well as eosinophil functions, and suggest that normalhuman basophils possess functional
receptors for IL5.
I
L5 is a glycoprotein liberated from activated T cells, and
has been shown to possess a variety ofbiological activities
on different cell types (reviewed in reference 1) . Besides its
action on T andB lymphocytes, IL5 acts on eosinophil lineages
to induce their selective proliferation and differentiation in
humans as well as in mice (2, 3) . Furthermore, IL5 stimu-
lates mature eosinophils to enhance their functional activi-
ties, such as phagocytosis, motility, and the synthesis of bio-
logically active molecules (4, 5) . In as much as substantial
evidence strongly indicates a close relationship between
basophils and eosinophils, and the fact thatwe observed that
two eosinophilopoietic factors (granulocyte/macrophage [GM]-
CSF and IL3) enhanced basophil histamine release (6), we
address the question ofwhether IL5 does modulate basophil
function . In this paper, we show that IL5 enhances hista-
mine release from human basophils at picomolar concen-
trations.
Materials and Methods
Materials.
￿
Chemicals used in the experiments were purchased
as previously described (6) . Purified human (h) (7) and mouse (8)
rIIL5, produced by the Suntory Institute of Biomedical Research
(Mishima, Osaka, Japan), was kindly donated by Dr. T Honjo,
University of Kyoto (Kyoto, Japan) .
Histamine Release . Histamine release experiments were per-
formed as described in the preceding report (6) . Briefly, leukocytes
were separated from normal peripheral blood by dextran sedimen-
tation, and were incubated in the presence of various concentra-
tions of rIIr5 (400,ul) at 37°C. Incubation was carried out for 30
min, unless otherwise indicated, and histamine release was initi-
ated by the addition of 100 itl of secretagogues . After additional
incubation for 45 min at 37°C, supernatants were collected by cen-
trifugation, and released histamine was measured by an automated
fluorometric technique. Enhancement ofhistamine release by IIr5
was calculated by the following formula, as previously described
(6) : percent enhancement = 100x (histamine released with a
stimulus plus 11,5 - histamine released with a stimulus)/total hista-
mine content . Each experiment was performed in duplicate or
triplicate.
Purification ofBasophik
￿
In some experiments, purified basophils
were used instead of crude leukocyte preparations. The details o£
the purification procedure will be described elsewhere (Yamaguchi,
M ., K . Hirai, Y Morita, T Takaishi, K . Ohta, S . Suzuki, K.
Motoyoshi, O. Kawanami, and K . Ito, manuscript submitted for
publication) . In brief, basophils were separated from normal pe-
ripheral bloodby discontinuous Pencoll (Pharmacia Fine Chemicals,
Uppsala, Sweden) gradients with densities of 1.070 and 1.079 g/ml,
followed by negative panning selections using anti-Leu-5b (CD2),
anti-Leu-12 (CD19), and anti-Leu-M3 (CD14) (Becton Dickinson
&Co ., Mountain View, CA) . Purified basophil suspensions were
prepared with a purity of -90% . Neutrophils and lymphocytes
were the most frequent contaminating cells, and preparations con-
tained only small numbers of eosinophils (<0.5%) .
Results and Discussion
We first tested whether rhlL5 itself directly induced hista-
mine release from basophils . However, we observed no
significant release in the presence of 3 nM of rhIIL5 (n =
5) . We next studied the effect of rhIIr5 on histamine release
evoked by various secretagogues . Pre-incubation of leukocytes
with rhIIr5 resulted in the dose-dependent augmentation of
histamine release initiated by anti-IgE, FMLP, or ionophore
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Figure 1 .
￿
Enhancement of histamine release by rhl1r5 upon stimula-
tion with anti-IgE, FMLP, or ionophore A23187. leukocytes were pre-
incubated for 30 min with serially diluted rhI1,5 and then stimulated with
(" ) anti-IgE (1:3,000; n - 7), (O) FMLP (10-5M; n = 5), or (") iono-
phore A23187 (0 .2 Ag/ml ; n = 5) . Control release in the absence of rhI1r5
was 39 .6 t 5.6% (mean ± SEM) for anti-IgE, 38.0 t 6.9% for FMLP,,
and 27 .8 ± 10.7% for ionophore A23187. The bar represents SEM.
A23187 (Fig . 1) . Maximal enhancement expressed as a per-
cent increase against total histamine content was 19.5 ± 3.3%
(mean ± SEM; range, 6.4-32.7%) for anti-IgE;19.5 ± 2.8%
(range, 12.6-27.2%) for FMLP ; and 19.6 ± 0.9% (range,
17.1-22.3%) for ionophore A23187 . Irrespective ofthe stimuli
used, the enhancement occurred at similar concentrations of
rhILT5 ; half-maximal enhancement was observed at concen-
trations ranging from 10 to 30 pM, and the enhancement
was observed in a dose-dependent fashion between 0.3 and
300 pM .
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Figure 2 .
￿
Enhancement of histamine release from purifiedbasophils by
rhllr5 . Basophils were purified from normal peripheral blood and tested
as described above. (A) Anti-IgE (1:3,000 ; n = 5); (B) FMLP (10 - 5 M ;
n = 5) ; (C) ionophore A23187 (0.2 jig/ml ; n = 5) . Control release in
the absence of rhIL5 was 27.4 t 6.2% (mean ± SEM) for anti-IgE, 40.0
t 4.9% for FMLP, and 27.2 ± 5.2% for ionophore A23187 . The bar
represents SEM .
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Since several lines of evidence have demonstrated that 11'5
activates mature eosinophils and certain eosinophil products
such as major basic protein to induce histamine release from
human basophils (9), we ex#mined whether rhII'5 directly
acted on basophils rather than indirectly via contaminating
eosinophils . We performed similar experiments using purified
basophils instead of crudeleukocyte preparations, and observed
rhI1'5-induced dose-dependent augmentation comparable with
that found using crude leukocyte preparations (Fig. 2) .
When rhI1r5 was removed by washing before stimulation,
we still observed the enhancement, indicating that the pres-
ence of rhILr5 was not required for augmentation to occur
during the release process (data not shown) . We reported in
the preceding paper that the enhancement of histamine re-
lease by IL.3 or GM-CSF was time dependent and took place
rapidly (6) . The enhancement by IL-5 was also a rapid process.
Apparent enhancement was observed when the cells were pre-
treated with rhI1'5 for 1 min, and the augmentation reached
maximum within 30 min ofpre-treatment with rhILr5 (Fig . 3) .
Human IL'5 shares high sequence homology with murine
IL5 (ti70%a at the amino acid level), and hence, murine IL-5
is activeonhuman eosinophils (10) . A similar situation was
found in basophils; murine 11'5 also enhanced human basophil
histamine release (Fig . 4) .
Both eosinophils and basophils, constituting elements of
circulating white blood cells, play crucial roles in hypersensi-
tivity reactions. Both cells share several properties . First, some
eosinophil-specific proteins, such as major basic protein and
lysophospholipase (Charcot-Leiden crystal), also exist in
basophils (11, 12) . Second, both cells generate LTC4 as a
major product of aracbidonic acid metabolism . Third, in clonal
analyses, the coexistence of eosinophils and basophils has been
observed in single colonies derived from human hemopoietic
precursors (13, 14) . Finally, hybrid cells, which possess both
eosinophilic andbasophilic granules, have been found in semi-
solid cultures (14) as well as in the peripheral blood of pa-
tients with chronic myelogenous leukemia (15) . These ob-
servations collectively indicate the close relationship between
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Figure 3 .
￿
Time dependence of the enhancement of histamine release
by rhIL5 . Leukocytes were pre-incubated with 300 pM of rhID5 for var-
ious periods of time and then stimulated withFMLP (10-5 M) . Data are
the averages of duplicate determinations of an experiment representative
of four separate experiments .00
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Figure4.
￿
Enhancement ofhistamine release by murine 11,5 . Leukocytes
were preincubated for 30 min with serially diluted murine (" ) or human
(O) rlIr5, and then stimulatedwith anti-IgE (1:3,000). Data are the averages
ofduplicate determinations of an experiment representative of three sepa-
rate experiments .
eosinophils and basophils, and raise the possibility that both
cells might potentially derive from a common precursor.
Production of eosinophils is controlled by three eo-
sinophilopoietic factors, including IL3, GM-CSF, and IL5 .
In the preceding paper, we reported that basophil histamine
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release was amplified by 11,3 and GM-CSF, while G-CSF,
M-CSF, and 114 had no effect at all (6) . In the present paper,
we demonstrate that 11,5 also enhances basophil histamine
release. It is ofinterest that all three eosinophilopoietic factors
also stimulate basophils to enhance histamine release, and these
observations provide additional evidence to support the no-
tion that basophils and eosinophils closely resemble each other;
the same hemopoietic growth factors regulate biological func-
tions of both eosinophils and basophils .
The fact that IL5 modulates basophil functions in vitro
indicates a possible mechanism of in vivo regulation by IL5
in terms of clinical manifestations of hypersensitivity reac-
tions. Migrated basophils at the sites of inflammation are be-
lieved to contribute to IgE-mediated late-phase reactions. In
concert with IIr3 and GM-CSF, and possibly with IL8, known
to stimulate basophils to trigger histamine release (16) and
to induce chemoaatis (17), IL5 modulates basophil histamine
release and could participate in exacerbation and prolonga-
tion ofhypersensitivity reactions . In fact,HA as well as IL3
and GM-CSF, induced migration of purified basophils (M .
Yamaguchi et al., unpublished observation) .
In conclusion, the observation that IL5 is active on basophils
at picomolar concentrations is a novel finding and suggests
the presence of functional receptors for 111,5 on normal
basophils . These findings add new insight into mechanisms
controlling hypersensitivity reactions as well as human
basophilopoiesis .
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